The financial picture is quite encouraging. Sales are projected to start slowly, but this is due to the necessity of receiving CE mark. We need a second round of financing in April 2000 to start the sales on the market. The company has financed all machinery and tools and does not have any credit line. The original investors have been financing the development.
We want to finance growth mainly through cash flow. Collection days is very important. We do not want to let our average collection days get above 45 under any circumstances. We must maintain gross profit margins of 90% at the least, and hold marketing costs to no more than 5%. We are planning to receive tax exemption from the Canton of Vaud, which means that only federal tax is due to payment on net profit (around 10%) in FY2000. In the following years the total tax rate will be 25%
7.1 Important Assumptions
The financial plan depends on important assumptions, most of which are shown in the following table. The key underlying assumptions are:
- We assume a slow-growth economy, without major recession.
- We assume that there are no unforeseen changes in technology to make products immediately obsolete.
- We assume access to equity capital and financing sufficient to maintain our financial plan.
| General Assumptions |
| Plan Month |
1 |
2 |
3 |
| Current Interest Rate |
6.00% |
6.00% |
6.00% |
| Long-term Interest Rate |
5.00% |
5.00% |
5.00% |
| Tax Rate |
11.67% |
10.00% |
11.67% |
| Other |
0 |
0 |
0 |
7.2 Key Financial Indicators
The following chart shows changes in key financial indicators: sales, gross margin, operating expenses, collection days, and inventory turnover.
7.3 Break-even Analysis
Our Break-even Analysis is based on running costs, the "burn-rate" costs we incur to keep the business running, not on theoretical fixed costs that would be relevant only if we were closing. Between payroll, rent, utilities, and basic marketing costs, we think the number shown in the table is a good estimate of fixed costs.
The Break-even Analysis shows that Bioring has a good balance of fixed costs and sufficient sales strength to remain healthy. The essential insight here is that our sales level seems to be running comfortably above break-even.
| Break-even Analysis |
|
|
| Monthly Units Break-even |
38 |
| Monthly Revenue Break-even |
$23,710 |
|
|
| Average Per-Unit Revenue |
$625.00 |
| Average Per-Unit Variable Cost |
$35.00 |
| Estimated Monthly Fixed Cost |
$22,382 |
7.4 Projected Profit and Loss
We expect sales to hit $2,500,000 for this year. It should increase to $10 million by the second year of this plan, as net earnings increase steadily. Our high sales volume has lowered our cost of goods and increased our gross margin. This increase in gross margin is important to profitability.

| Pro Forma Profit and Loss |
| Direct Cost of Sales |
$140,000 |
$560,000 |
$840,000 |
| Production Payroll |
$14,730 |
$70,200 |
$74,500 |
| Other |
$0 |
$0 |
$0 |
| Total Cost of Sales |
$154,730 |
$630,200 |
$914,500 |
|
|
|
|
| Gross Margin |
$2,345,270 |
$9,369,800 |
$14,085,500 |
| Gross Margin % |
93.81% |
93.70% |
93.90% |
|
|
|
|
|
|
|
|
| Sales and Marketing Payroll |
$65,250 |
$78,000 |
$181,250 |
| Advertising/Promotion |
$0 |
$35,000 |
$50,000 |
| Travel |
$6,000 |
$24,000 |
$35,000 |
| Miscellaneous |
$13,500 |
$20,000 |
$30,000 |
| Total Sales and Marketing Expenses |
$84,750 |
$157,000 |
$296,250 |
| Sales and Marketing % |
3.39% |
1.57% |
1.98% |
|
|
|
|
| General and Administrative Payroll |
$29,115 |
$65,500 |
$359,000 |
| Sales and Marketing and Other Expenses |
$0 |
$0 |
$0 |
| Depreciation |
$72,000 |
$96,000 |
$96,000 |
| Patent fees for PCT |
$10,000 |
$70,000 |
$70,000 |
| Utilities |
$3,150 |
$5,400 |
$6,000 |
| Insurance |
$9,000 |
$12,000 |
$13,000 |
| Rent |
$33,300 |
$444,400 |
$45,000 |
| Payroll Taxes |
$27,274 |
$75,925 |
$178,688 |
| Other General and Administrative Expenses |
$0 |
$0 |
$0 |
| Total General and Administrative Expenses |
$183,839 |
$769,225 |
$767,688 |
| General and Administrative % |
7.35% |
7.69% |
5.12% |
|
|
|
|
| Other Payroll |
$0 |
$90,000 |
$100,000 |
| Consultants |
$0 |
$0 |
$0 |
| Royalties Dr. A.Kalangos |
$0 |
$125,000 |
$493,750 |
| Total Other Expenses |
$0 |
$215,000 |
$593,750 |
| Other % |
0.00% |
2.15% |
3.96% |
|
|
|
|
|
|
|
|
| Profit Before Interest and Taxes |
$2,076,681 |
$8,228,575 |
$12,427,813 |
| EBITDA |
$2,148,681 |
$8,324,575 |
$12,523,813 |
| Interest Expense |
$0 |
$0 |
$0 |
| Taxes Incurred |
$207,668 |
$822,858 |
$1,449,911 |
|
|
|
|
| Net Profit/Sales |
74.76% |
74.06% |
73.19% |
7.5 Projected Cash Flow
We expect to manage cash flow over the next three years with $100,000 of new investment in April 2000. This additional financing resources are required to finance the working capital.

| Pro Forma Cash Flow |
|
|
|
|
| Cash from Operations |
|
|
|
| Cash Sales |
$625,000 |
$2,500,000 |
$3,750,000 |
| Cash from Receivables |
$1,414,063 |
$6,117,188 |
$10,328,125 |
| Subtotal Cash from Operations |
$2,039,063 |
$8,617,188 |
$14,078,125 |
|
|
|
|
| Additional Cash Received |
|
|
|
| Sales Tax, VAT, HST/GST Received |
$0 |
$0 |
$0 |
| New Current Borrowing |
$0 |
$0 |
$0 |
| New Other Liabilities (interest-free) |
$0 |
$0 |
$0 |
| New Long-term Liabilities |
$0 |
$0 |
$0 |
| Sales of Other Current Assets |
$0 |
$0 |
$0 |
| Sales of Long-term Assets |
$0 |
$0 |
$0 |
| New Investment Received |
$100,000 |
$0 |
$0 |
| Subtotal Cash Received |
$2,139,063 |
$8,617,188 |
$14,078,125 |
|
|
|
|
|
|
|
|
| Expenditures from Operations |
|
|
|
| Cash Spending |
$109,095 |
$303,700 |
$714,750 |
| Bill Payments |
$333,104 |
$2,128,248 |
$3,167,861 |
| Subtotal Spent on Operations |
$442,199 |
$2,431,948 |
$3,882,611 |
|
|
|
|
| Additional Cash Spent |
|
|
|
| Sales Tax, VAT, HST/GST Paid Out |
$0 |
$0 |
$0 |
| Principal Repayment of Current Borrowing |
$0 |
$0 |
$0 |
| Other Liabilities Principal Repayment |
$0 |
$0 |
$0 |
| Long-term Liabilities Principal Repayment |
$0 |
$0 |
$0 |
| Purchase Other Current Assets |
$0 |
$0 |
$0 |
| Purchase Long-term Assets |
$0 |
$100,000 |
$200,000 |
| Dividends |
$0 |
$0 |
$0 |
| Subtotal Cash Spent |
$442,199 |
$2,531,948 |
$4,082,611 |
|
|
|
|
| Cash Balance |
$1,725,864 |
$7,811,104 |
$17,806,618 |
7.6 Projected Balance Sheet
As shown in the balance sheet in the following table, we expect a healthy growth in net worth. The monthly projections are in the appendix.

| Pro Forma Balance Sheet |
|
|
|
|
| Current Assets |
|
|
|
| Cash |
$1,725,864 |
$7,811,104 |
$17,806,618 |
| Accounts Receivable |
$460,938 |
$1,843,750 |
$2,765,625 |
| Inventory |
$19,250 |
$77,000 |
$115,500 |
| Other Current Assets |
$0 |
$0 |
$0 |
| Total Current Assets |
$2,206,051 |
$9,731,854 |
$20,687,743 |
|
|
|
|
| Long-term Assets |
|
|
|
| Long-term Assets |
$280,000 |
$380,000 |
$580,000 |
| Accumulated Depreciation |
$72,000 |
$168,000 |
$264,000 |
| Total Long-term Assets |
$208,000 |
$212,000 |
$316,000 |
| Total Assets |
$2,414,051 |
$9,943,854 |
$21,003,743 |
|
|
|
|
|
|
|
|
| Current Liabilities |
|
|
|
| Accounts Payable |
$61,038 |
$185,123 |
$267,111 |
| Current Borrowing |
$0 |
$0 |
$0 |
| Other Current Liabilities |
$0 |
$0 |
$0 |
| Subtotal Current Liabilities |
$61,038 |
$185,123 |
$267,111 |
|
|
|
|
| Long-term Liabilities |
$0 |
$0 |
$0 |
| Total Liabilities |
$61,038 |
$185,123 |
$267,111 |
|
|
|
|
| Paid-in Capital |
$742,500 |
$742,500 |
$742,500 |
| Retained Earnings |
($258,500) |
$1,610,513 |
$9,016,231 |
| Earnings |
$1,869,013 |
$7,405,718 |
$10,977,901 |
| Total Capital |
$2,353,013 |
$9,758,731 |
$20,736,632 |
| Total Liabilities and Capital |
$2,414,051 |
$9,943,854 |
$21,003,743 |
|
|
|
|
| Net Worth |
$2,353,013 |
$9,758,731 |
$20,736,632 |
7.7 Business Ratios
Our ratios look healthy and solid. Gross margin is projected to stay above 95%, and return on assets and return on equity are very sound. Debt and liquidity ratios also look very good, with debt to net worth running at respectively 0,34, 0,05 and 0,02. The projections, if we make them, are those of a very solid company. Industry profile ratios based on the Standard Industrial Classification (SIC) code 3842, Surgical Appliances and Supplies, are shown for comparison.

| Ratio Analysis |
| Sales Growth |
0.00% |
300.00% |
50.00% |
6.10% |
|
|
|
|
|
| Accounts Receivable |
19.09% |
18.54% |
13.17% |
25.00% |
| Inventory |
0.80% |
0.77% |
0.55% |
15.90% |
| Other Current Assets |
0.00% |
0.00% |
0.00% |
38.00% |
| Total Current Assets |
91.38% |
97.87% |
98.50% |
78.90% |
| Long-term Assets |
8.62% |
2.13% |
1.50% |
21.10% |
| Total Assets |
100.00% |
100.00% |
100.00% |
100.00% |
|
|
|
|
|
| Current Liabilities |
2.53% |
1.86% |
1.27% |
37.60% |
| Long-term Liabilities |
0.00% |
0.00% |
0.00% |
20.20% |
| Total Liabilities |
2.53% |
1.86% |
1.27% |
57.80% |
| Net Worth |
97.47% |
98.14% |
98.73% |
42.20% |
|
|
|
|
|
| Sales |
100.00% |
100.00% |
100.00% |
100.00% |
| Gross Margin |
93.81% |
93.70% |
93.90% |
47.70% |
| Selling, General & Administrative Expenses |
19.05% |
31.98% |
31.76% |
28.20% |
| Advertising Expenses |
0.00% |
0.35% |
0.33% |
1.60% |
| Profit Before Interest and Taxes |
83.07% |
82.29% |
82.85% |
4.90% |
|
|
|
|
|
| Current |
36.14 |
52.57 |
77.45 |
2.03 |
| Quick |
35.83 |
52.15 |
77.02 |
1.35 |
| Total Debt to Total Assets |
2.53% |
1.86% |
1.27% |
57.80% |
| Pre-tax Return on Net Worth |
88.26% |
84.32% |
59.93% |
5.70% |
| Pre-tax Return on Assets |
86.02% |
82.75% |
59.17% |
13.40% |
|
|
|
|
|
| Net Profit Margin |
74.76% |
74.06% |
73.19% |
n.a |
| Return on Equity |
79.43% |
75.89% |
52.94% |
n.a |
|
|
|
|
|
| Accounts Receivable Turnover |
4.07 |
4.07 |
4.07 |
n.a |
| Collection Days |
56 |
56 |
75 |
n.a |
| Inventory Turnover |
3.15 |
11.64 |
8.73 |
n.a |
| Accounts Payable Turnover |
6.46 |
12.17 |
12.17 |
n.a |
| Payment Days |
27 |
20 |
25 |
n.a |
| Total Asset Turnover |
1.04 |
1.01 |
0.71 |
n.a |
|
|
|
|
|
| Debt to Net Worth |
0.03 |
0.02 |
0.01 |
n.a |
| Current Liab. to Liab. |
1.00 |
1.00 |
1.00 |
n.a |
|
|
|
|
|
| Net Working Capital |
$2,145,013 |
$9,546,731 |
$20,420,632 |
n.a |
| Interest Coverage |
0.00 |
0.00 |
0.00 |
n.a |
|
|
|
|
|
| Assets to Sales |
0.97 |
0.99 |
1.40 |
n.a |
| Current Debt/Total Assets |
3% |
2% |
1% |
n.a |
| Acid Test |
28.28 |
42.19 |
66.66 |
n.a |
| Sales/Net Worth |
1.06 |
1.02 |
0.72 |
n.a |
| Dividend Payout |
0.00 |
0.00 |
0.00 |
n.a |